Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulatorDeepens Axsome’s broad ...

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...

As Neuphoria Therapeutics considers its options in the wake of the failure of its phase 3 social anxiety program, an ...

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...

WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...

Anavex Life Sciences faces regulatory setbacks, pipeline doubts, and dilution risks. Click here to read my latest analysis of ...

Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

(MENAFN- GlobeNewsWire - Nasdaq) NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No ...